IBT
ARDX icon

International Biotechnology Trust’s Ardelyx ARDX Stock Holding History

International Biotechnology Trust’s Portfolio ARDX Stock Details ARDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-78,000
Closed -$591K – 71
2021
Q2 		$591K Buy
+78,000
New +$577K 0.16% 58

Other funds holding ARDX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
OCM
Orchard Capital Management Chicago, Illinois $103M AUM 65.87% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

International Biotechnology Trust's ARDX Position: Q3 2021 in Review

International Biotechnology Trust sold out of Ardelyx (ARDX) in Q3 2021, closing a stake of 78,000 shares — an estimated $591K sold.

International Biotechnology Trust first reported a position in ARDX in Q2 2021 and held it in 1 quarter. The position peaked at $591K in Q2 2021. 108 funds tracked by Wall St. Rank hold ARDX as of Q3 2021.

  • International Biotechnology Trust reported no remaining Ardelyx position as of Q3 2021 after selling out during the quarter.
  • International Biotechnology Trust sold 78,000 Ardelyx shares in Q3 2021, an estimated $591K.
  • International Biotechnology Trust first reported a position in Ardelyx in Q2 2021 and held it in 1 quarter.
  • International Biotechnology Trust's Ardelyx position peaked at $591K in Q2 2021.
  • 108 funds tracked by Wall St. Rank held Ardelyx as of Q3 2021.

Based on International Biotechnology Trust's 13F filing for Q3 2021, filed 12 Nov 2021.